viewNektan PLC

Nektan gaining momentum through 2019


In a third quarter trading update on 5 April, the firm reported a record performance in its B2B division, which saw revenues rise 75%

Online gambling

Quick facts: Nektan PLC

Price: - -

Market: AIM
Market Cap: -

• Delivers premium casino content to game operators
• B2B and BRC business arms
• E-Lite platform distributes cutting-edge content

What Nektan does

Nektan PLC (LON:NKTN) aggregates and delivers premium casino content from the industry's leading game providers to game operators.

Using its proprietary technology, it delivers either a fully managed white label casino solution to its B2C partners or acts as a content distributor to its B2B partners.

The white label solution is delivered via its Evolve platform, while the E-Lite platform distributes cutting-edge content.

Both platforms leverage Nektan's market bonusing and business intelligence tools.

Inflexion points

• On 17 April, the company completed the sale of a majority stake in US operation Respin. Nektan has sold 57.5% of Respin to Alternative Investment Partners Limited (AIP), a different buyer than originally planned, for £300,000 cash plus the provision of US$800,000 in working capital

• In a third quarter trading update on 5 April the firm reported revenues has risen 5.9% year-on-year. The performance was helped by a record revenue performance in its B2B division, which rose 75% to £350,000

• Nektan said it expects an improvement in trading for the final quarter of its current fiscal year

• In March, Nektan said it had signed up Mo Play, the betting partner of Manchester United football club, to its B2B E-lite platform, which provides gaming operators with more than 700 of the industry's most cutting-edge, mobile-ready HTML5 games content

Blue Sky

Speaking to Proactive in May, Nektan’s chief executive Lucy Buckley said following a 43% reduction in the group’s debt commitments to £6.45mln it was now in a “strong position” with a “firm foundation to really accelerate” its international expansion.

She added that the sale of the group’s majority stake in its US business meant its would still be able to benefit from future revenue growth but Nektan was no longer funding the business and could focus on growing its “core” European and Asian businesses.

“Our focus for the rest of the year is profitability…really focus on that and reducing our debt. We have an established business model and established technology, we just need to increase the number of partners in our distribution”.

With shares trading at 11p as of 10 May, Nektan carries a market cap of £12.1mln.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Nektan PLC named herein, including the promotion by the Company of Nektan PLC in any Content on the Site, the Company receives from said issuer...



Revive Therapeutics: Analyst sees 'substantial upside potential' as key...

Proactive Research analyst Ed Stacey says Revive Therapeutics (CSE:RVV)(OTCQB:RVVTF) is a speciality life sciences company focussed on repurposing drugs for rare and infectious diseases and has a pipeline of of three main platforms. One of them is Bucillamine (BUC) which is a medication with a...

1 week, 5 days ago

2 min read